Financial Consulate’s Agios Pharmaceuticals AGIO Stock Holding History

Financial Consulate’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.13K	Buy	+64	New	+$2.24K	﹤0.01%	1105

Other funds holding AGIO

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Financial Consulate's AGIO Position: Q3 2026 in Review

Financial Consulate opened a new position in Agios Pharmaceuticals (AGIO) in Q3 2026: 64 shares worth $2.13K. The stake represents ﹤0.01% of the portfolio and ranks #1105 among its holdings.

111 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

Financial Consulate held 64 shares of Agios Pharmaceuticals worth $2.13K as of Q3 2026.
Agios Pharmaceuticals was a new Financial Consulate position in Q3 2026.
Agios Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1105 holding.
111 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.